AlloVir, Inc. (ALVR)
AlloVir, Inc. operates in the Biotechnology industry of the Healthcare sector, headquartered in Waltham, MA, US. The stock last traded at $9.81, up 4.14% on the session, giving a market capitalisation of $49.5M. On trailing twelve-month figures it carries a trailing P/E of -5.74, a net margin of 0.0%. Its beta of 0.62 implies it has historically moved less than the broad market.
AlloVir, Inc. is a biotechnology company in the clinical stage, dedicated to researching and developing allogeneic, "off-the-shelf" multi-virus specific T-cell (VST) therapies. Its primary goal is to prevent and treat severe diseases caused by viral infections. The company's lead product, posoleucel, is an allogeneic, ready-to-use VST therapy designed to combat several significant viruses, including BK virus, cytomegalovirus, adenovirus, Epstein-Barr virus, human herpesvirus 6, and JC virus. Beyond this flagship candidate, AlloVir's pipeline features additional investigational treatments in various stages of development. These include ALVR106, which targets respiratory syncytial virus, influenza, parainfluenza virus, and human metapneumovirus; ALVR109, developed to address SARS-CoV-2 and COVID-19; ALVR107, for treating hepatitis B; and ALVR108. Established in 2013, the company was initially known as ViraCyte, Inc. before officially rebranding as AlloVir, Inc. in May 2019. Its headquarters are located in Waltham, Massachusetts.
AlloVir, Inc. is most often compared with the following Healthcare names: